Compare Novartis AG (NVS) vs Workday Inc (WDAY) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Workday (WDAY) trades at $186.28, down 4.86% on the day, but maintains a bullish technical signal with strong moving average support. The company reported Q2 2026 EPS of $2.75, beating estimates of $2.61, marking the third consecutive quarterly beat. Revenue growth remains robust, projected to reach $10.2B in 2026, while net income margin improved to 12.32%. Recent news highlights AI adoption gains and a leadership position in cloud HCM suites.

The outlook is positive with analyst consensus favoring a Buy rating and a $204.52 price target, implying potential upside. Key opportunities include AI-driven subscription growth and expanding margins, but risks involve high valuation multiples and competitive pressures in the enterprise software space. Execution on AI initiatives and sustained profitability are critical for continued stock appreciation.